Fate Therapeutics to Present at the 2017 Piper Jaffray Healthcare Conference
November 21 2017 - 8:00AM
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, announced today that Scott Wolchko, President and Chief
Executive Officer, will present at the 2017 Piper Jaffray
Healthcare Conference in New York on Tuesday, November 28, 2017 at
12:50 p.m. ET.
A live webcast of the presentation will be
available through the investor relations section of the Company's
website at www.fatetherapeutics.com. Following the live webcast, an
archived replay will be available on the Company's website.
About Fate Therapeutics, Inc. Fate Therapeutics
is a clinical-stage biopharmaceutical company dedicated to the
development of programmed cellular immunotherapies for cancer and
immune disorders. The Company's hematopoietic cell therapy pipeline
is comprised of NK- and T-cell immuno-oncology programs, including
off-the-shelf product candidates derived from engineered induced
pluripotent cell lines, and immuno-regulatory programs, including
product candidates to prevent life-threatening complications in
patients undergoing hematopoietic cell transplantation and to
promote immune tolerance in patients with autoimmune disease. Its
adoptive cell therapy programs are based on the Company's
novel ex vivo cell programming approach, which it applies
to modulate the therapeutic function and direct the fate of immune
cells. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern
Investor Relations, Inc. 212.362.1200 christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024